Last reviewed · How we verify
HNC364
At a glance
| Generic name | HNC364 |
|---|---|
| Also known as | HNC364 injectable suspension |
| Sponsor | Guangzhou Henovcom Bioscience Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Relative Bioavailability Study of HNC364 Injectable Suspension (PHASE1)
- A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HNC364 CI brief — competitive landscape report
- HNC364 updates RSS · CI watch RSS
- Guangzhou Henovcom Bioscience Co. Ltd. portfolio CI